202522-04-1

Basic information

• Product Name: Benzonitrile, 3-ethyl-4-formyl- (9CI)
• Synonyms: Benzonitrile, 3-ethyl-4-formyl- (9CI);3-Ethyl-4-formyl-benzonitrile
• CAS NO: 202522-04-1
• Molecular Formula: C₁₀H₉NO
• Molecular Weight: 159.18456
• Product Categories: ALDEHYDE
• Mol File: 202522-04-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 296.7±28.0 °C(Predicted)
• Appearance: /
• Density: 1.08±0.1 g/cm3(Predicted)
• CAS DataBase Reference: Benzonitrile, 3-ethyl-4-formyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzonitrile, 3-ethyl-4-formyl- (9CI)(202522-04-1)
• EPA Substance Registry System: Benzonitrile, 3-ethyl-4-formyl- (9CI)(202522-04-1)

Safety Data

• Hazardous Substances Data: 202522-04-1(Hazardous Substances Data)

Usage

General Description

Benzonitrile, 3-ethyl-4-formyl- (9CI) is a chemical compound with the molecular formula C10H9NO. It is a yellow-colored liquid that is commonly used as a building block in organic synthesis. Benzonitrile, 3-ethyl-4-formyl- (9CI) is often utilized in the production of pharmaceuticals, agrochemicals, and dyes. It is known for its strong odor and should be handled with care due to its potential toxicity. Additionally, benzonitrile, 3-ethyl-4-formyl- (9CI) is also used as an intermediate compound in the manufacturing of various industrial chemicals and is a versatile reagent in chemical reactions.

Upstream product

• 175278-30-5 1-iodo-2-ethyl-4-bromobenzene 
• 557-21-1 zinc(II) cyanide 
• 1114808-89-7 4-bromo-2-ethylbenzaldehyde 
• 170230-87-2 4'-amino-3'-ethylbenzonitrile 
• 4421-08-3 3-methoxy-4-hydroxybenzonitrile 
• 959934-76-0 tert-butyl (2E)-3-(4-cyano-2-methoxyphenyl)acrylate 
• 21962-45-8 4-formyl-3-methoxy-benzonitrile 
• 84102-89-6 4-formyl-3-hydroxybenzonitrile 
• 959984-36-2 5-cyano-2-formyl-phenyl trifluoromethanesulfonate 

Downstream Products

• 202522-03-0 3-ethyl-4-(hydroxymethyl)benzonitrile 
• 202522-07-4 4-cyano-2-ethylbenzylamine 
• 202522-06-3 N-(4-cyano-2-ethylbenzyl)phthalimide 
• 959984-38-4 4-(2-acetyl-3-oxobut-1-en-1-yl)-3-ethylbenzonitrile 
• 1187028-46-1 3-ethyl-4-formylbenzoic acid 

Relevant articles and documents

SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINAMIDES AND USE THEREOF

1,6-Naphthyridine or 8-azaquinazoline derivatives (I) are new. 1,6-Naphthyridine or 8-azaquinazoline derivatives of formula (I) are new. D : N or CR 4>; R 4> : H, F, CF 3 or 1-4C alkyl; Ar : 5-R 5>-6-R 6>-2-methyl-4-oxo-4H-1-benzopyran-8-yl; 3-R 6>-4-R 8>-1-naphthyl optionally substituted with 1-3 of R 7>; 7-R 6>-8-R 8>-5-quinolinyl optionally substituted with 1-2 of R 7>; or 2-R 9>-3-R 10>-4-R 8>-5-R 6>-phenyl; R 5> : H, F, Cl, CN, NO 2, CF 3 or 1-4C alkyl; R 6> : H or F; R 7> : halo, 1-4C alkyl, CF 3, 1-4C alkoxy or OCF 3; R 8> : CN or NO 2; R 9> : H or halo; optionally fluorinated 1-4C alkyl, 1-4C alkoxy, 1-4C alkylthio of di(1-4C alkyl)amino; or phenyl optionally substituted with halo, 1-4C alkyl or CF 3; R 10> : H, halo or 1-4C alkyl; R 1> : optionally fluorinated 1-4C alkyl; R 2> : 1-6C alkyl optionally substituted with 3-7C cycloalkyl or F; or SO 2R 11>; R 11> : 1-6C alkyl, CF 3 or 3-7C cycloalkyl; or phenyl or heteroaryl optionally substituted with 1-2 of halo, CN, 1-4C alkyl, CF 3, 1-4C alkoxy and/or OCF 3; R 3> : H, F, CF 3 or 1-4C alkyl. An independent claim is also included for a process for preparing (I). [Image] ACTIVITY : Hypotensive; Cardiant; Hepatotropic; Nephrotropic; Cerebroprotective. MECHANISM OF ACTION : Mineralocorticoid receptor (MR) antagonist. 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2-methyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide had an IC 50 of 35 nM when tested on cells expressing a GAL4-MR chimera.

MS565: A SPECT tracer for evaluating the brain penetration of BAF312 (siponimod)

Abstract BAF312 (siponimod) is a sphingosine-1-phosphate (S1P) receptor modulator in clinical development for the treatment of multiple sclerosis, with faster organ/tissue distribution and elimination kinetics than its precursor FTY720 (fingolimod). Our a

SUBSTITUTED-4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINAMIDES AND USE THEREOF

The present application relates to novel substituted 4-aryl-1,4-dihydro-1,6-naphthyridine-3-carboxamides, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.